Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
← catalyst calendarNCT06848946 · readout ≤ 11 d
Sponsored by Glaukos Corporation (industry) · GKOS — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
132estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-13 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Glaucoma, Open-angle
- Ocular Hypertension (OHT)
- Phacoemulsification Cataract Surgery
Interventions
- Combination product: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
- Procedure: Sham procedure in conjunction with cataract surgery
Primary outcome
what the primary-completion date above is the date OFChange from baseline in mean diurnal IOP
measured 3 Months
Permalink · GKOS's whole pipeline · Catalyst calendar · Every registered study · What changed